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Introduction
Desialylated low-density lipoprotein (LDL), a modi¢ed lipoprotein occurring in vivo, has a low content of sialic acid, which is a terminal saccharide of the biantennary sugar chains of apolipoprotein B (apoB). Desialylated LDL is smaller in particle size, higher in density, less electronegative, lower in a⁄nity for the LDL receptor and more potent in cellular lipid accumulation compared with native LDL. 1 Moreover, LDL desialylation in vivo may be a primary step of atherogenic lipoprotein modi¢cation. 2 So far, only limited information has been available as to whether or not desialylated LDL is a risk factor for cardiovascular disease. Orekhov et al. reported that the sialic acid concentration in LDL was signi¢cantly lower in patients with cardiovascular disease than in healthy subjects, 1 but this result has been challenged by other studies. 3--5 A major impediment in the clinical study of desialylated LDL resides in the methodology of its estimation. Desialylated LDL has been measured by a combination of time-consuming ultracentrifugal isolation of LDL and subsequent chemical determination of sialic acid. Here we propose measurement of plasma desialylated apoB-containing lipoproteins using a simple precipitation method.
Method
ApoB-containing lipoproteins were isolated and measured as follows. EDTA plasma (300 mL) was mixed with 30 mL of a precipitation reagent consisting of 10 g/L dextran sulphate and 71.1g/L magnesium chloride, according to the method suggested by the Centers for Disease Control and Prevention. After immediate centrifugation at 2400 g for 10 min at room temperature, the precipitate containing very low-density lipoprotein (VLDL) and LDL was washed twice with 5 mL of the precipitation reagent and then dissolved in 300 mL of 50 mmol/L Tris-HCl (pH 7.4) containing 1g/L EDTA and neuraminidase (1375 IU/L, Kyokuto Pharmaceutical Industrial Co. Ltd.,Tokyo, Japan).
Sialic acid in the obtained solution was assayed using an auto-analyzer (Cobas Mira, Roche Diagnostics,Tokyo, Japan) and a commercial sialic acid determination kit (Kyokuto). In this assay, N-acetyl neuraminic acid (NANA) was released from the bound form of sialic acid by neuraminidase and then cleaved into N-acetyl mannosamine and pyruvic acid by NANA-aldolase. Pyruvic acid was reduced to lactic acid in the presence of lactic acid dehydrogenase and NADH. Generated NAD þ was monitored by absorbance at 340 nm between 5 and 12.5 min of the reaction. Standard solutions of sialic acid (NANA; 1.0 g/L, 3.23 mmol/L) provided by the manufacturer, and the reagent blank were analysed in each run.
Control plasma was obtained in the presence of 1g/L EDTA from 96 apparently healthy volunteers (men, n ¼ 46, age [mean7SD] 46.8714.2 years; women, n ¼ 50, 42.4713.5 years) after a 12-h overnight fast and then assayed immediately. Hyperlipidaemic plasma was obtained from 136 patients who visited Ehime University Hospital for various purposes. The hyperlipidaemic patients were subclassi¢ed into types IIa (n ¼ 46; total cholesterol X5.69 mmol/L, triglyceride o1.69 mmol/L), IIb (n ¼ 43; total cholesterol X5.69 mmol/L, triglyceride 1.69--11.29 mmol/L), and IV (n ¼ 47; total cholesterol o5.69 mmol/L, triglyceride 1.69--11.29 mmol/L), according to the WHO criteria.
Plasma apoB was measured by an immunoturbidimetric assay (Daiichi Pure Chemicals, Tokyo, Japan). Comparison between the groups was undertaken using the Mann--Whitney U test.
Results
Sialic acid concentrations in apoB-containing lipoproteins in plasma in normal subjects and hyperlipidaemic patients of types IIa, IIb, and IVare shown in Figure 1a The content (percent, shown as mean7SD) of sialic acid in apoB, estimated from the concentration of sialic acid in apoB-containing lipoproteins and apoB in plasma, was compared among the same study groups (Figure 1b) . The di¡erence was not signi¢cant between the groups of normal (2.0370.41%) and all (unclassi-¢ed) types of hyperlipidaemia (2.0970.35%). Type IIa showed a decrease (1.8670.27%, Po0.0001), while type IIb showed a moderate decrease (1.9770.26%, Po0.02). On the other hand, type IV showed a signi¢cant increase (2.2870.41%, Po0.002).
Neuraminidase concentration was su⁄cient at 1000 IU/L to release sialic acid from precipitated apoBcontaining lipoproteins (data not shown). The standard curve was linear to 50 mg/L of sialic acid in plasma apoB-containing lipoproteins. Within-run imprecision (CV, n ¼10) was 2.6% and 4.9% at 26.7 and 14.3 mg/L, respectively. Between-run imprecision (n ¼10) was 3.8% and 4.2% at 18.4 and 9.6 mg/L, respectively.
Discussion
Compared with conventional ultracentrifugation methods, the major merit of the present approach is simplicity, speed, and applicability to most laboratories. In the literature, two sandwich assays based on the interaction of a lectin and the terminal galactose of desialylated LDL have been reported. 5, 6 Both assays utilized anti-apoB antibodies to capture or detect lipoproteins, and therefore measure desialylated apoB-containing lipoproteins as an approximation of desialylated LDL, which is similar to our approach. In these cases, one can expect a partial contribution of sialic acid in VLDL to the result. In fact, we found that the level of sialic acid in apoB-containing lipoproteins was elevated in hyperlipidaemic subjects not only of types IIa or type IIb, but also of type IV, in which LDL did not increase (Figure 1a) .
The content of sialic acid in apoB was signi¢cantly lower in the type IIa group than in the healthy controls, indicating the increase of desialylated LDL in type IIa hyperlipidaemia (Figure 1b) . The elevation of the content of sialic acid in apoB in the type IV group indicates a possible contribution of sialic acid in sugar-modi¢ed apolipoproteins other than apoB, such as apoCIII and apoE, which is noteworthy when this method is applied to hypertriglyceridaemic subjects.
